The Federal Antimonopoly service have agreed on the first two pharmaceutical manufacturers limit selling price for a cure for coronavirus infection. The cost of the drug will be reduced at least twice.
The FAS Russia agreed on the first two pharmaceutical manufacturers limit selling price for a drug for the treatment of COVID-19 international nonproprietary names (INN) favipiravir— noted in the press release of the Ministry.
As reported by the anti-monopolists, the price tag for a pack of 50 tablets in subjects of the Russian Federation will not exceed 5 500 rubles. When conducting the economic analysis was based on prices in countries where favipiravir is in circulation.
Currently, the approval of the Ministry of health for the treatment of coronavirus infection has received three national drug. This “Avidavit” (production of RDIF and “Chimera”), “Coronaves” (“R-Pharm”), and “Replevin” (“Promomed”). All drugs have a temporary registration until January 1, 2021. The active substance in them is the same — favipiravir, the same as their Japanese namesake “ancestor”.
Earlier it was reported that “Replevin” will cost in pharmacies 12 320 rubles, wrote NEWS.ru